Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Data-driven cis-bispecific antibody-drug conjugates for solid tumour cancers
Promatix Biosciences is an oncology drug discovery company developing next-generation bispecific antibody-drug conjugates through data-driven target pairing. Using a proteomics database and computational algorithms, the company identifies antigen combinations enabling selective tumour targeting, aiming to reduce…
AI-designed combination therapies for cancer
Big Picture Bio is a preclinical biotechnology company designing combination therapies for cancer. Its generative model simulates how tumours, immune cells and surrounding tissue interact, and is used to predict which drug combinations, and which sequences of treatment, are most likely to suppress resistant cancer…
Oxygen-generating nanoparticles to overcome hypoxia in solid tumours
StimOxyGen is a preclinical-stage biotechnology company developing pH-responsive nanoparticle formulations to address tumour hypoxia, a major barrier to effective cancer treatment. The technology uses a biodegradable polymer coating that dissolves in the acidic tumour microenvironment, transiently generating localised…
Clinical-stage biotech developing treatments for multiple myeloma
CellCentric is a clinical-stage biopharmaceutical company developing inobrodib, a first-in-class oral inhibitor of the p300/CBP transcription co-activation proteins, for relapsed and refractory multiple myeloma. Inobrodib has been evaluated in over 400 patients and holds FDA Fast Track and orphan drug designations.…
Immuno-oncology therapies targeting the nfP2X7 cancer receptor
Biosceptre is a UK-headquartered clinical-stage biotechnology company developing cancer therapeutics based on its proprietary nfP2X7 platform. The nfP2X7 receptor is a non-functional form of P2X7 expressed on cancer cells across a broad range of tumour types, enabling targeted therapeutic approaches. The pipeline…
Small molecule therapeutics targeting lipid-signalling pathways
Artelo Biosciences is a clinical-stage biopharmaceutical company developing small molecule therapeutics that modulate lipid-signalling pathways, including the endocannabinoid system. Its pipeline includes ART27.13, a peripherally selective cannabinoid receptor agonist in Phase 2 for cancer-associated anorexia and…
ADC pipeline targeting mutant stem cells in blood cancers
Alethio Therapeutics Limited is a preclinical-stage biotechnology company developing antibody-drug conjugates for myeloproliferative neoplasms, a group of chronic blood cancers. Its pipeline targets the mutant stem and progenitor cells that drive disease progression and fibrosis, with the aim of modifying rather than…
Quantum-informed computational design of covalent drug candidates
Axiom Therapeutics is a London biotechnology company using molecular physics and machine learning to design covalent small-molecule medicines. Its computational drug-discovery platform models interactions between reactive compounds and biological targets, helping design selective inhibitors for difficult-to-drug…
T cell immunotherapies for infectious disease, cancer and autoimmunity
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific T cell immunotherapies for chronic infectious diseases, autoimmune conditions, and cancer. Its pipeline is built on four proprietary viral vector and synthetic immunotherapy platforms and includes clinical candidates…
Off-the-shelf cancer immunotherapies targeting solid tumours
Scancell is a clinical-stage biotech developing active immunotherapies and antibody-based therapeutics for cancer. Its pipeline spans DNA cancer vaccines, peptide immunotherapies and tumour-specific monoclonal antibodies targeting glycans expressed on cancer cells. Lead programmes iSCIB1+ and Modi-1 are in Phase 2…
Global commercialisation of specialty, hospital and rare disease medicines
ADVANZ PHARMA is a global pharmaceutical company focused on the commercialisation of specialty, hospital and rare disease medicines, partnering with biopharma and pharmaceutical development companies to bring treatments to patients. The company's portfolio spans therapeutic areas including hepatology,…
Targeted antibody therapeutics for cancer and autoimmune disease
Medannex is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics targeting annexin-A1, a protein implicated in cancer progression, autoimmunity, and inflammation. Its lead asset, MDX-124, is the first therapeutic antibody to target annexin-A1 and is currently being evaluated in the…
Specialist immunology CRO for preclinical biotherapeutic drug discovery
RoukenBio is a specialist contract research organisation providing preclinical immunology services to biopharmaceutical companies worldwide. Its team offers cell-based bioassay development, functional characterisation of antibody therapeutics and complex biologics, cell line engineering, and CMC-quality potency assay…
Historical gene therapy platform targeting cancer stem cells
Cellinta was a University of Edinburgh-linked biotechnology company established to develop selective gene therapies targeting cancer stem cells in solid tumours. Its approach used stem-cell-specific regulatory sequences to restrict therapeutic gene expression to tumour-driving cell populations. The technology…
Immunology CRO for immuno-oncology, autoimmunity and inflammation
Celentyx is a contract research organisation providing bespoke assay services in human immunology to pharmaceutical and biotechnology clients. Operating from sites in Birmingham and Oxford, the company uses primary human cells and tissues from healthy donors and patients to support drug discovery across…
Individualised neoantigen-based cell therapies for ovarian and solid cancers
Singula Bio is a seed-stage biotechnology company developing individualised, neoantigen-based cell therapies for patients with solid tumours, with an initial focus on ovarian cancer and other difficult-to-treat malignancies. The company's approach harnesses a patient's own immune system to target mutations that appear…
Oncolytic viral therapies engineered for intravenous cancer treatment
Theolytics is a clinical-stage biotechnology company developing oncolytic viral therapies for cancer. Its phenotypic screening platform enables the discovery and development of adenovirus-based candidates optimised for intravenous delivery and specific patient populations. The lead programme, THEO-260, entered Phase…
AI platform for bone marrow morphology analysis
Ground Truth Labs is an Oxford-based computational pathology company applying machine learning and computer vision to decode disease in bone marrow tissue. Its platform quantifies morphological markers including fibrosis, blasts, and plasma cells at slide and cell level, and identifies novel prognostic patterns…
Oncolytic vaccinia virus platform targeting refractory solid tumours
VacV Biotherapeutics is a cancer immunotherapy company developing engineered oncolytic Vaccinia virus-based therapeutics for the treatment of solid tumours. Spun out of Barts Cancer Institute and Queen Mary University of London, the company's platform uses a modified Vaccinia virus to simultaneously destroy tumour…
Fragment-based drug discovery platform for oncology and CNS disorders
Astex Pharmaceuticals is a drug discovery and development company pioneering fragment-based drug discovery through its proprietary Pyramid platform, applied to oncology and central nervous system disorders. Astex maintains an internal pipeline alongside active collaborations with MSD targeting KRAS and p53. The…